Most Read Articles
Christina Lau, 13 Sep 2018

In patients diagnosed with atrial fibrillation (AF), late initiation of oral anticoagulant (OAC) therapy is common and is associated with a significantly increased risk of stroke, according to a study led by the Chinese University of Hong Kong (CUHK).

16 Apr 2016
New drug applications approved by US FDA as of 1 - 15 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 07 Sep 2018

Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.

Pearl Toh, 20 Sep 2018
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.

Diets rich in cottonseed oil improve fasting cholesterol, triglyceride

08 Nov 2018
Used cooking oil must be stored properly for safe re-use.

A high-fat diet rich in cottonseed oil (CSO) appears to effectively improve cholesterol and triglyceride concentrations, a recent study has found. In contrast, olive oil (OO)-rich diets exert no such effects.

Researchers randomly assigned 15 normal-weight men (mean age 21.6±2.58 years; mean body mass index, 24.27±2.81 kg/m2) to receive either CSO-rich or OO-rich diets for 5 days before crossover. Diets were 50-percent fat and blood samples were collected during pre- and postdiet visits.

Fasting levels of total cholesterol dropped from previsit values following the CSO diet (148.40±6.39 to 135.93±6.31 mg/dL; p<0.05). No such effect was observed during the OO-intervention arm (149.71±6.38 vs 140.93±6.92 mg/dL).

Similar effects on fasting low-density lipoprotein cholesterol (LDL-C) levels were observed for the CSO (92.20±5.57 to 78.13±5.60 mg/dL; p<0.05) and OO (91.14±6.87 to 85.64±6.29 mg/dL) interventions. The same was true for fasting triglyceride levels (CSO: 80.11±4.91 to 56.37±5.46 mg/dL; p<0.05; OO: 74.51±8.38 to 64.08±6.87 mg/dL).

In contrast, the CSO diet led to significant increases in the mean fasting high-density lipoprotein cholesterol (HDL-C) levels (46.67±2.41 to 50.24±2.20 mg/dL; p<0.05), while the OO diet remained ineffective (48.92±2.44 to 48.21±1.92 mg/dL).

In terms of between-diet comparisons, researchers found that LDL-C (78.13±5.61 vs 85.64±6.29 mg/dL; p<0.05) and triglyceride (56.37±5.46 vs 64.08± 6.87 mg/dL; p<0.05) concentrations were significantly lower following the CSO vs OO diets.

The present findings underline the value of CSO in improving fasting lipid profiles and its potential in reducing the risk of conditions such as obesity, type 2 diabetes and nonalcoholic fatty liver disease, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 13 Sep 2018

In patients diagnosed with atrial fibrillation (AF), late initiation of oral anticoagulant (OAC) therapy is common and is associated with a significantly increased risk of stroke, according to a study led by the Chinese University of Hong Kong (CUHK).

16 Apr 2016
New drug applications approved by US FDA as of 1 - 15 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 07 Sep 2018

Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.

Pearl Toh, 20 Sep 2018
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.